Form 8-K · Current report
Abbott Laboratories 8-K, filed Oct 21, 2026
- Filed
- CIK
- 0000001800
- Accession no.
- 0001628280-26-066601
Summary
Abbott Laboratories reported third-quarter 2026 sales growth of 14.5% on a reported basis and 7.0% on a comparable basis, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, and reaffirmed the midpoint of its full-year 2026 adjusted diluted EPS guidance while tightening the range to $5.50–$5.55. Chairman and CEO Robert B. Ford attributed the results to balanced growth across the portfolio and cited a pipeline of new product approvals.
Key points
- Third-quarter 2026 reported sales rose 14.5% and comparable sales rose 7.0%, with total reported sales of $13.0 billion.
- Abbott projects full-year 2026 comparable sales growth of approximately 6.0% and tightened its adjusted diluted EPS guidance to $5.50–$5.55.
- The quarter included FDA approval of Libre Duo, a dual glucose-ketone biowearable sensor, and of the TactiFlex Duo Ablation Catheter, plus CE Mark for the Amulet 360 Left Atrial Appendage Occluder.
- Abbott acquired cancer diagnostics company Exact Sciences on March 23, 2026, and now reports its sales as the Cancer Diagnostics business.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On October 21, 2026, Abbott Laboratories announced its results of operations for the third quarter 2026. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.